International Journal of Molecular Sciences

Journal Browser

► Journal Browser

Special Issue Editors

Dr. Theodoros Karampitsakos

E-Mail Website
Guest Editor

Ubben Center and Laboratory for Pulmonary Fibrosis Research, Morsani College of Medicine, University of South Florida, Tampa, FL 33620, USA
Interests: respiratory medicine

Dr. Brenda M. Juan-Guardela

E-Mail Website
Guest Editor

Assistant Professor and Medical Director of Respiratory Care at Tampa General Hospital Pulmonary, Critical Care and Sleep Medicine Morsani College of Medicine, University of South Florida, Tampa, FL 33620, USA
Interests: immunogenomics; ILD; COPD

Special Issue Information

Dear Colleagues,

The burden of lung diseases is steadily increasing. Coronavirus disease-19 (COVID-19) and post-COVID-19 syndrome have had devastating effects on health-care systems, and chronic lung diseases are now included in the top three causes of death. Despite considerable progress in the last few years, high-quality mechanistic evidence able to be translated into the molecular endotyping of patients and personalized medicine approaches is still an unmet need for most lung diseases. This Special Issue aims to shed light on the molecular pathophysiology of lung diseases and focus on experimental data with potential for translation into clinical practice, such as molecular biomarkers or targeted therapies.

Dr. Theodoros Karampitsakos
Dr. Brenda M. Juan-Guardela
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

biomarkers
asthma
COPD
pulmonary fibrosis
post-COVID-19 interstitial lung disease
pathogenesis
personalized medicine

Published Papers (1 paper)

Review

14 pages, 641 KiB

Open AccessReview

Personalized Medicine in Severe Asthma: From Biomarkers to Biologics

by Chun-Yu Chen, Kang-Hsi Wu, Bei-Cyuan Guo, Wen-Ya Lin, Yu-Jun Chang, Chih-Wei Wei, Mao-Jen Lin and Han-Ping Wu

Int. J. Mol. Sci. 2024, 25(1), 182; https://doi.org/10.3390/ijms25010182 - 22 Dec 2023

Viewed by 2413

Abstract

Severe asthma is a complex and heterogeneous clinical condition presented as chronic inflammation of the airways. Conventional treatments are mainly focused on symptom control; however, there has been a shift towards personalized medicine. Identification of different phenotypes driven by complex pathobiological mechanisms (endotypes), especially those driven by type-2 (T2) inflammation, has led to improved treatment outcomes. Combining biomarkers with T2-targeting monoclonal antibodies is crucial for developing personalized treatment strategies. Several biological agents, including anti-immunoglobulin E, anti-interleukin-5, and anti-thymic stromal lymphopoietin/interleukin-4, have been approved for the treatment of severe asthma. These biological therapies have demonstrated efficacy in reducing asthma exacerbations, lowering eosinophil count, improving lung function, diminishing oral corticosteroid use, and improving the quality of life in selected patients. Severe asthma management is undergoing a profound transformation with the introduction of ongoing and future biological therapies. The availability of novel treatment options has facilitated the adoption of phenotype/endotype-specific approaches and disappearance of generic interventions. The transition towards precision medicine plays a crucial role in meticulously addressing the individual traits of asthma pathobiology. An era of tailored strategies has emerged, allowing for the successful targeting of immune-inflammatory responses that underlie uncontrolled T2-high asthma. These personalized approaches hold great promise for improving the overall efficacy and outcomes in the management of severe asthma. This article comprehensively reviews currently available biological agents and biomarkers for treating severe asthma. With the expanding repertoire of therapeutic options, it is becoming increasingly crucial to comprehend the influencing factors, understand the pathogenesis, and track treatment progress in severe asthma. Full article

(This article belongs to the Special Issue Molecular Pathophysiology of Lung Diseases)

► Show Figures

Figure 1

Journal Menu

Journal Browser

Molecular Pathophysiology of Lung Diseases

Share This Special Issue

Special Issue Editors

Special Issue Information

Keywords

Published Papers (1 paper)

Review

Further Information

Guidelines

MDPI Initiatives

Follow MDPI